Yesterday, ImmunoGen Inc. (IMGN) announced that it has licensed its technology to Amgen Inc. (AMGN) to develop anticancer drugs. The deal allows Amgen exclusive rights to use ImmunoGen’s maytansinoid targeted antibody payload [TAP] technology for developing anticancer therapeutics to an undisclosed target found on solid tumors. According to the terms of the deal, ImmunoGen will receive [...] (IMGN) Amgen Taps ImmunoGen License